Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI) secured a second $1 million strategic private placement. As a result, the company has raised a total of $2 million in February 2026. This funding strengthens its financial position and supports upcoming regulatory and clinical milestones.
The company plans to use the capital to advance preparations for its Phase 3b clinical trial of NurOwn. In addition, the funding will support working capital and other corporate needs. Therefore, Brainstorm can continue progressing without disruption.
Key Highlights of the Strategic Placement
The second strategic placement reflects strong investor confidence and disciplined structuring.
-
Market-Aligned Pricing: Investors purchased common stock at $0.60 per share, closely matching the recent closing price of $0.615.
-
High-Conviction Warrants: The deal includes 120% warrant coverage at an exercise price of $1.00 per share. This price represents a clear valuation target.
-
Structured Liquidity: Investors will fund the placement in up to eight installments. Consequently, the company can manage cash flow more predictably.
Together, these terms provide flexibility while maintaining alignment with market conditions.
Supporting Phase 3b Trial Readiness
Brainstorm strategic placement activity signals growing market confidence. According to President and CEO Chaim Lebovits, raising $2 million within one week helps establish a valuation floor. Moreover, it extends the company’s operational runway.
With this financing, Brainstorm can focus on regulatory preparation and clinical execution. At the same time, management continues to address legacy liabilities with discipline. As a result, the company strengthens its path toward late-stage development.
Overall, the Brainstorm strategic placement enhances financial stability. More importantly, it enables continued progress in developing stem cell therapies for neurodegenerative diseases.
Read Also: Tooth Fairy Raises Average Payout to $5.84 in 2026, Says Delta Dental Plans Association Poll
